Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | ATR | Q13535 | 5/20 | 0.33 |
| ▸ | RET | P07949 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PDE1A | P54750 | 3/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21152701 | 0.79 | GAA (0.51) | GAACYP4F2CYP4A11ATRRET | |
| SCHEMBL21002088 | 0.76 | GAA (0.49) | GAACYP4F2CYP4A11RETALDH1A1 | |
| SCHEMBL17675453 | 0.76 | GAA (0.49) | GAACYP4F2CYP4A11ATRRET | |
| SCHEMBL15445676 | 0.74 | GAA (0.47) | GAACYP4F2CYP4A11ATRRET | |
| SCHEMBL25389805 | 0.72 | GAA (0.46) | GAACYP4F2CYP4A11RETALDH1A1 | |
| SCHEMBL15334772 | 0.70 | GAA (0.40) | GAACYP4F2CYP4A11ATRRET | |
| SCHEMBL17675662 | 0.69 | GAA (0.42) | GAACYP4F2CYP4A11ATRALDH1A1 | |
| SCHEMBL3082406 | 0.69 | GAA (0.42) | GAACYP4F2CYP4A11PDE1APDE1B | |
| SCHEMBL22552469 | 0.68 | GAA (0.54) | GAACYP4F2CYP4A11RETALDH1A1 | |
| SCHEMBL29050006 | 0.68 | GAA (0.47) | GAACYP4F2CYP4A11RETALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202826-B2 | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | REDX PHARMA PLC (GB) | 2025-01-21 | — | — | US | disclosed |
| US-20230365549-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2023-11-16 | — | — | US | disclosed |
| US-20230365549-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2023-11-16 | — | — | US | disclosed |
| US-20230365549-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2023-11-16 | — | — | US | disclosed |
| US-11643408-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | REDX PHARMA PLC (GB) | 2023-05-09 | — | — | US | disclosed |
| US-11643408-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | REDX PHARMA PLC (GB) | 2023-05-09 | — | — | US | disclosed |
| US-11643408-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | REDX PHARMA PLC (GB) | 2023-05-09 | — | — | US | disclosed |
| EP-3204378-B3 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2022-05-25 | — | — | EP | disclosed |
| EP-3204378-B3 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2022-05-25 | — | — | EP | disclosed |
| US-20210046076-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2021-02-18 | — | — | US | disclosed |
| US-10793560-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | REDX PHARMA PLC (GB) | 2020-10-06 | — | — | US | disclosed |
| EP-3204378-B1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2019-07-10 | — | — | EP | disclosed |
| EP-3204378-B1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2019-07-10 | — | — | EP | disclosed |
| US-20180319788-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2018-11-08 | — | — | US | disclosed |
| US-20170275276-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2017-09-28 | — | — | US | disclosed |
| US-20170275276-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2017-09-28 | — | — | US | disclosed |
| US-20170275276-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | REDX PHARMA PLC (GB) | 2017-09-28 | — | — | US | disclosed |
| EP-3204378-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | Redx Pharma PLC (GB) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016055786-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055786-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | REDX PHARMA PLC (GB) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202826-B2 | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | WNT1, WNT3, CTNNB1 | GAA 3180/4885LIPE 4855/4885CYP4F2 3607/4885 |
| US-10793560-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | WNT1, WNT3, CTNNB1 | GAA 3462/4885LIPE 4858/4885CYP4F2 3054/4885 |
| US-20230365549-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | GAA 3180/4885LIPE 4855/4885CYP4F2 3607/4885 |
| US-20180319788-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | GAA 3462/4885LIPE 4858/4885CYP4F2 3054/4885 |
| US-20170275276-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | GAA 3462/4885LIPE 4858/4885CYP4F2 3054/4885 |
| US-20210046076-A1 | N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALING PATHWAY | WNT1, WNT3, CTNNB1 | GAA 3180/4885LIPE 4855/4885CYP4F2 3607/4885 |
| US-11643408-B2 | N-pyridinyl acetamide derivatives as inhibitors of the WNT signaling pathway | WNT1, WNT3, CTNNB1 | GAA 3180/4885LIPE 4855/4885CYP4F2 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.